Pathology and Laboratory Medicine, VA Boston Healthcare System, West Roxbury.
Clin Infect Dis. 2013 Oct;57(8):1175-81. doi: 10.1093/cid/cit424. Epub 2013 Jun 20.
Single molecular or multistep assays (glutamate dehydrogenase, toxin A/B, ± molecular) are recommended for the diagnosis of CDI in patients with clinically significant diarrhea. Rapid and accurate tests can improve resource allocations and improve patient care. Enzyme immunoassay (EIA) for toxins A/B is too insensitive for use as a stand-alone assay. This guideline will examine the use of molecular tests and multitest algorithms for the diagnosis of Clostridium difficile infection (CDI). These new tests, alone or in a multistep algorithm consisting of >1 assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save money overall by initiating appropriate treatment and infection control protocols sooner and by possibly reducing length of hospital stay. We recommend testing only unformed stool in patients with clinically significant diarrhea by a molecular method or by a 2- to 3-step algorithm.
推荐对有临床显著腹泻的患者使用单分子或多步骤检测法(谷氨酸脱氢酶、毒素 A/B、±分子)进行 CDI 的诊断。快速而准确的检测可以改善资源分配并提高患者的护理质量。毒素 A/B 的酶免疫测定(EIA)因其灵敏度不足而不能作为独立的检测方法使用。本指南将研究分子检测法和多步骤算法在艰难梭菌感染(CDI)诊断中的应用。这些新的检测方法,无论是单独使用还是作为包含 >1 种检测方法的多步骤算法使用,都比旧的 EIA 检测法更为昂贵;然而,通过更早地开始实施适当的治疗和感染控制方案,以及可能缩短住院时间,快速而准确的检测可以节省总体费用。我们建议仅对有临床显著腹泻的患者使用分子方法或 2-3 步算法检测未成形的粪便。